Information:
Fel:
ID
34426
Beskrivning
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations; ODM derived from: https://clinicaltrials.gov/show/NCT01287754
Länk
https://clinicaltrials.gov/show/NCT01287754
Nyckelord
Versioner (1)
- 2019-01-17 2019-01-17 -
Rättsinnehavare
GSK group of companies
Uppladdad den
17 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Non-Small Cell Lung Cancer NCT01287754
Eligibility Non-Small Cell Lung Cancer NCT01287754
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT01287754
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
adult patients, >/=18 years of age
boolean
ID.2
Item
locally advanced or metastatic (stage iii/iv) non-small cell lung cancer with egfr mutations
boolean
ID.3
Item
measurable disease according to recist criteria
boolean
ID.4
Item
ecog performance status 0-2
boolean
ID.5
Item
adequate haematological, renal and liver function
boolean
ID.6
Item
previous chemotherapy or therapy against egfr for metastatic disease
boolean
ID.7
Item
history of another malignancy, except for in situ carcinoma of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis
boolean
ID.8
Item
symptomatic cerebral metastases
boolean
ID.9
Item
pre-existing parenchymal lung disease such as pulmonary fibrosis
boolean
ID.10
Item
concomitant use of coumarins
boolean